India, Nov. 22 -- Jubilant Life Sciences' wholly-owned subsidiary -- Jubilant Pharma has redeemed the principal amount of $100 million on pro-rata basis out of $300 million notes at a redemption price of 102.43750% together with the accrued interest till date.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.

Published by HT Digital Content Services with permission from Accord Fintech....